Office of the Director, National Institutes of Health; Office of Biotechnology Activities; Recombinant DNA Research; Notice of a Meeting of an NIH Blue Ribbon Panel, 21359 [E8-8474]

Download as PDF Federal Register / Vol. 73, No. 77 / Monday, April 21, 2008 / Notices D. Pet Food Processing Standards The AFSS initiative is intended to cover the entire spectrum of agency activities from preapproval of food additives for use in feed, to establishing limits for feed contaminants, providing education and training, and conducting inspections and taking enforcement actions for ensuring compliance with agency regulations. Some basic elements of an animal feed safety system are described at: https://www.fda.gov/ohrms/ dockets/98fr/03n–0312–bkg0002.pdf. Would standards based on a riskbased, preventive, and comprehensive feed control measures approach, such as the approach described as an element of FDA’s AFSS initiative, adequately address the processing standards requirement of section 1002(a) of FDAAA? If so, what aspects of procurement, processing and distribution should be included in such an approach? Should such standards be developed and applied to all animal feeds rather than be limited to pet food? DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Pregnancy and Neonatology Study Section, June 2, 2008, 8 a.m. to June 3, 2008, 3 p.m., Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC, 20015 which was published in the Federal Register on April 4, 2008, 73 FR 18539–18542. The meeting will be held one day only June 2, 2008, from 8 a.m. to 5 p.m. The meeting location remains the same. The meeting is closed to the public. Dated: April 14, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–8450 Filed 4–18–08; 8:45 am] BILLING CODE 4140–01–M III. Other Information for the Public Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES FDA has posted additional information for the May 13, 2008, public meeting on the CVM Web site at https:// www.fda.gov/cvm. The agency may make additional background material available to the public and will post that information on the CVM Web site as well. Additionally, background material relating to AFSS, including previous drafts of the AFSS Framework document, is available at https:// www.fda.gov/cvm/AFSS.htm. National Institutes of Health IV. Transcripts rwilkins on PROD1PC63 with NOTICES FDA will prepare a meeting transcript that will be entered into the docket. FDA anticipates that transcripts will be available approximately 30 business days after the meeting. The transcript will also be available for public examination at the Division of Dockets Management (HFA–305), 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Dated: April 15, 2008. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. 08–1155 Filed 4–16–08; 3:48 pm] BILLING CODE 4160–01–S VerDate Aug<31>2005 17:14 Apr 18, 2008 Jkt 214001 Office of the Director, National Institutes of Health; Office of Biotechnology Activities; Recombinant DNA Research; Notice of a Meeting of an NIH Blue Ribbon Panel There will be a meeting of the NIH Blue Ribbon Panel to advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories (NEIDL) at the Boston Medical Center. The meeting will be held on Friday, May 2, 2008, at the National Institutes of Health, Building 31, Floor 6C, Conference Room 10, 31 Center Drive, Bethesda, Maryland 20892, from 8:30 a.m. to approximately 11:30 a.m. The National Research Council Committee that provided technical input on the NIH’s Draft Supplementary Risk Assessments and Site Suitability Analyses for the NEIDL will participate in discussions with Panel members regarding the scope and design of additional studies that may be needed to assess risk associated with the siting and operation of the NEIDL. For further information concerning this meeting contact Ms. Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, Office of the Director, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892–7985, 301–496–9838, lewallla@od.nih.gov. PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 21359 The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed above in advance of the meeting. Any interested person may file written comments with the panel by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. NIH campus security procedures require that all visitor vehicles, including taxicabs and hotel and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. An agenda and any additional information for the meeting will be posted on the agency’s Web site: https://www.nih.gov/about/director/acd/ index.htm. Background information may be obtained by contacting NIH OBA by email oba@od.nih.gov. Dated: April 14, 2008. Amy P. Patterson, Director, Office of Biotechnology Activities. [FR Doc. E8–8474 Filed 4–18–08; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency Agency Information Collection Activities: Submission for OMB Review; Comment Request Federal Emergency Management Agency, DHS. ACTION: Notice; 30-day notice and request for comments; Telephone Survey, OMB 1660–0057, Revision of a currently approved collection. AGENCY: SUMMARY: The Federal Emergency Management Agency (FEMA) has submitted the following information collection to the Office of Management and Budget (OMB) for review and clearance in accordance with the requirements of the Paperwork Reduction Act of 1995. The submission describes the nature of the information collection, the categories of respondents, the estimated burden (i.e., the time, effort and resources used by respondents to respond) and cost, and E:\FR\FM\21APN1.SGM 21APN1

Agencies

[Federal Register Volume 73, Number 77 (Monday, April 21, 2008)]
[Notices]
[Page 21359]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8474]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Office of 
Biotechnology Activities; Recombinant DNA Research; Notice of a Meeting 
of an NIH Blue Ribbon Panel

    There will be a meeting of the NIH Blue Ribbon Panel to advise on 
the Risk Assessment of the National Emerging Infectious Diseases 
Laboratories (NEIDL) at the Boston Medical Center. The meeting will be 
held on Friday, May 2, 2008, at the National Institutes of Health, 
Building 31, Floor 6C, Conference Room 10, 31 Center Drive, Bethesda, 
Maryland 20892, from 8:30 a.m. to approximately 11:30 a.m.
    The National Research Council Committee that provided technical 
input on the NIH's Draft Supplementary Risk Assessments and Site 
Suitability Analyses for the NEIDL will participate in discussions with 
Panel members regarding the scope and design of additional studies that 
may be needed to assess risk associated with the siting and operation 
of the NEIDL.
    For further information concerning this meeting contact Ms. Laurie 
Lewallen, Advisory Committee Coordinator, Office of Biotechnology 
Activities, Office of the Director, National Institutes of Health, 6705 
Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-9838, 
lewallla@od.nih.gov.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed above in 
advance of the meeting. Any interested person may file written comments 
with the panel by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    NIH campus security procedures require that all visitor vehicles, 
including taxicabs and hotel and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one form 
of identification (for example, a government-issued photo ID, driver's 
license, or passport) and to state the purpose of their visit.
    An agenda and any additional information for the meeting will be 
posted on the agency's Web site: https://www.nih.gov/about/director/acd/
index.htm.
    Background information may be obtained by contacting NIH OBA by e-
mail oba@od.nih.gov.

    Dated: April 14, 2008.
Amy P. Patterson,
Director, Office of Biotechnology Activities.
[FR Doc. E8-8474 Filed 4-18-08; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.